CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer

Journal of Clinical Oncology

Volumn 30, Issue 35, 2012, Pages 4308-4316

  Weischer, Maren ^a   Nordestgaard, Børge G ^a   Pharoah, Paul ^b   Bolla, Manjeet K ^b   Nevanlinna, Heli ^e   Van't Veer, Laura J ^h   Garcia Closas, Montserrat ^c   Hopper, John L ^k   Hall, Per ^m   Andrulis, Irene L ⁿ   Devilee, Peter ⁱ   Fasching, Peter A ^o,p,t   Anton Culver, Hoda ^u   Lambrechts, Diether ^w   Hooning, Maartje ^j   Cox, Angela ^d   Giles, Graham G ^k,l   Burwinkel, Barbara ^q,r   Lindblom, Annika ^m   Couch, Fergus J ^y   Mannermaa, Arto ^f,g   Alnæs, Grethe Grenaker ^z   John, Esther M ^v   Dörk, Thilo ^s   Flyger, Henrik ^a   Dunning, Alison M ^b   Wang, Qin ^b   Muranen, Taru A ^e   Van Hien, Richard ^h   Figueroa, Jonine ^aa   Southey, Melissa C ^k   Czene, Kamila ^m   Knight, Julia A ⁿ   Tollenaar, Rob A E M ⁱ   Beckmann, Matthias W ^o,p   Ziogas, Argyrios ^u   Christiaens, Marie Rose ^x   Collée, Johanna Margriet ^j   Reed, Malcolm W R ^d   Severi, Gianluca ^k,l   Marme, Frederik ^q   Margolin, Sara ^m   Olson, Janet E ^y   Kosma, Veli Matti ^f,g   Kristensen, Vessela N ^v   Miron, Alexander ^ab   Bogdanova, Natalia ^s   Shah, Mitul ^b   Blomqvist, Carl ^e   Broeks, Annegien ^h   Sherman, Mark ^aa   Phillips, Kelly Anne ^k   Li, Jingmei ^ac   Liu, Jianjun ^ac   Glendon, Gord ⁿ   Seynaeve, Caroline ^j   Ekici, Arif B ^o   Leunen, Karin ^x   Kriege, Mieke ^j   Cross, Simon S ^d   Baglietto, Laura ^k,l   Sohn, Christof ^q   Wang, Xianshu ^y   Kataja, Vesa ^f,g   Børresen Dale, Anne Lise ^z   Meyer, Andreas ^s   Easton, Douglas F ^b   Schmidt, Marjanka K ^h   Bojesen, Stig E ^a   more..

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e UNIVERSITY OF HELSINKI   (Finland)

^f UNIVERSITY OF EASTERN FINLAND   (Finland)

^g KUOPIO UNIVERSITY HOSPITAL   (Finland)

^h NETHERLANDS CANCER INSTITUTE   (Netherlands)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k UNIVERSITY OF MELBOURNE   (Australia)

^l CANCER EPIDEMIOLOGY CENTRE   (Australia)

^m KAROLINSKA INSTITUTE   (Sweden)

ⁿ MOUNT SINAI HOSPITAL   (Canada)

^o UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^p Friedrich Alexander University Erlangen Nuremberg   (Germany)

^q UNIVERSITY OF HEIDELBERG   (Germany)

^r GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^s HANNOVER MEDICAL SCHOOL   (Germany)

^t UNIVERSITY OF CALIFORNIA   (United States)

^u UNIVERSITY OF CALIFORNIA   (United States)

^v CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^w UNIVERSITY OF LEUVEN   (Belgium)

^x UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^y MAYO CLINIC   (United States)

^z OSLO UNIVERSITY HOSPITAL   (Norway)

^aa NATIONAL CANCER INSTITUTE   (United States)

^ab DANA FARBER CANCER INSTITUTE   (United States)

^ac GENOME INSTITUTE OF SINGAPORE   (Singapore)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2; ESTROGEN RECEPTOR; PROTEIN SERINE THREONINE KINASE;

ADULT; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CAUCASIAN; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SECOND CANCER; BREAST TUMOR; CASE CONTROL STUDY; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; MIDDLE AGED; MUTATION; PROGNOSIS; PROSPECTIVE STUDY;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN-SERINE-THREONINE KINASES;

EID: 84870744620     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.7336     Document Type: Article

References (20)

1. Weischer M, Bojesen SE, Ellervik C, et al: CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: Meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol 26:542-548, 2008 (Pubitemid 351264346)
2. Zhang B, Beeghly-Fadiel A, Long J, et al: Genetic variants associated with breast-cancer risk: Comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol 12:477-488, 2011
3. Bartek J, Lukas J: Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3:421-429, 2003 (Pubitemid 38340288)
4. Nevanlinna H, Bartek J: The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 25:5912-5919, 2006 (Pubitemid 44453447)
5. Cybulski C, Górski B, Huzarski T, et al: CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75:1131-1135, 2004 (Pubitemid 39532081)
6. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al: Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55-59, 2002
7. CHEK2 Breast Cancer Case-Control Consortium: CHEK2*1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 74:1175-1182, 2004
8. Vahteristo P, Bartkova J, Eerola H, et al: A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 71:432-438, 2002 (Pubitemid 34800260)
9. Weischer M, Bojesen SE, Tybjaerg-Hansen A, et al: Increased risk of breast cancer associated with CHEK2*1100delC. J Clin Oncol 25:57-63, 2007 (Pubitemid 350003051)
10. Adank MA, Jonker MA, Kluijt I, et al: CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women. J Med Genet 48:860-863, 2011
11. Schmidt MK, Tollenaar RA, de Kemp SR, et al: Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol 25:64-69, 2007 (Pubitemid 350003052)
12. Azzato EM, Greenberg D, Shah M, et al: Prevalent cases in observational studies of cancer survival: Do they bias hazard ratio estimates? Br J Cancer 100:1806-1811, 2009
13. Colzani E, Liljegren A, Johansson AL, et al: Prognosis of patients with breast cancer: Causes of death and effects of time since diagnosis, age, and tumor characteristics. J Clin Oncol 29:4014-4021, 2011
14. de Bock GH, Schutte M, Krol-Warmerdam EM, et al: Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. J Med Genet 41:731-735, 2004 (Pubitemid 39389288)
15. Meyer A, Dörk T, Sohn C, et al: Breast cancer in patients carrying a germ-line CHEK2 mutation: Outcome after breast conserving surgery and adjuvant radiotherapy. Radiother Oncol 82:349-353, 2007 (Pubitemid 46350795)
16. Broeks A, de Witte L, Nooijen A, et al: Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. Breast Cancer Res Treat 83:91-93, 2004 (Pubitemid 38141897)
17. Broeks A, Braaf LM, Huseinovic A, et al: Identification of women with an increased risk of developing radiation-induced breast cancer: A case only study. Breast Cancer Res 9:R26, 2007
18. Meijers-Heijboer H, Wijnen J, Vasen H, et al: The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet 72:1308-1314, 2003 (Pubitemid 36530019)
19. Davey Smith G, Ebrahim S: 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32:1-22, 2003
20. Smith GD, Ebrahim S: Mendelian randomization: Prospects, potentials, and limitations. Int J Epidemiol 33:30-42, 2004 (Pubitemid 38528650)